Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTMDNASDAQ:CRMDNASDAQ:NAGENASDAQ:PHVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTMDbiote$3.54-0.3%$3.56$3.04▼$8.44$193.67M1.17191,779 shs52,214 shsCRMDCorMedix$12.38-1.8%$9.52$3.61▼$13.85$839.67M1.541.18 million shs934,881 shsNAGENiagen Bioscience$11.72-0.5%$8.37$2.31▼$12.07$923.18M1.94849,017 shs583,844 shsPHVSPharvaris$16.62-3.8%$15.52$11.51▼$25.50$903.57M-2.8674,854 shs67,922 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTMDbiote-0.28%+0.28%+8.92%-15.91%-47.09%CRMDCorMedix-1.82%-0.40%+37.10%+30.45%+135.36%NAGENiagen Bioscience-0.51%+6.74%+38.70%+52.41%+324.64%PHVSPharvaris-3.82%+7.50%-10.93%+7.57%-0.89%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBTMDbiote3.2769 of 5 stars3.55.00.00.00.03.31.3CRMDCorMedix1.6984 of 5 stars3.61.00.00.02.50.00.6NAGENiagen Bioscience0.8991 of 5 stars2.50.00.00.02.90.00.0PHVSPharvaris1.9495 of 5 stars3.53.00.00.02.20.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTMDbiote 3.00Buy$8.00125.99% UpsideCRMDCorMedix 3.14Buy$15.0021.16% UpsideNAGENiagen Bioscience 3.00Buy$13.0010.92% UpsidePHVSPharvaris 3.00Buy$40.67144.69% UpsideCurrent Analyst Ratings BreakdownLatest BTMD, PHVS, CRMD, and NAGE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025NAGENiagen BioscienceCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$13.005/14/2025PHVSPharvarisCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$28.00 ➝ $25.005/7/2025CRMDCorMedixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $15.005/6/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.004/29/2025PHVSPharvarisCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$28.004/9/2025CRMDCorMedixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.004/8/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/26/2025CRMDCorMedixRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$12.00 ➝ $12.003/26/2025CRMDCorMedixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $12.003/25/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/13/2025BTMDbioteCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $8.00(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTMDbiote$199.38M0.97$0.37 per share9.60($0.58) per share-6.10CRMDCorMedix$82.55M10.17N/AN/A$1.28 per share9.67NAGENiagen Bioscience$107.93M8.55N/AN/AN/A∞PHVSPharvarisN/AN/AN/AN/A$7.95 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTMDbiote$3.32M$0.6113.626.56N/A5.20%-32.41%22.26%8/14/2025 (Estimated)CRMDCorMedix-$46.34M$0.22N/A13.17N/AN/A-79.21%-64.68%8/13/2025 (Estimated)NAGENiagen BioscienceN/A$0.1768.94∞N/AN/AN/AN/AN/APHVSPharvaris-$109.18M-$3.01N/AN/AN/AN/A-38.52%-36.69%8/13/2025 (Estimated)Latest BTMD, PHVS, CRMD, and NAGE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025PHVSPharvaris-$0.80-$0.89-$0.09-$0.89N/AN/A5/7/2025Q1 2025BTMDbiote$0.06$0.08+$0.02$0.37$47.25 million$48.99 million5/6/2025Q1 2025CRMDCorMedix$0.25$0.30+$0.05$0.30$38.90 million$39.08 million4/7/2025Q4 2024PHVSPharvaris-$0.74-$0.68+$0.06-$0.68N/AN/A3/25/2025Q4 2024CRMDCorMedix$0.17$0.22+$0.05$0.22$27.46 million$30.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBTMDbioteN/AN/AN/AN/AN/ACRMDCorMedixN/AN/AN/AN/AN/ANAGENiagen BioscienceN/AN/AN/AN/AN/APHVSPharvarisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTMDbioteN/A1.501.16CRMDCorMedixN/A3.963.60NAGENiagen BioscienceN/AN/AN/APHVSPharvarisN/A19.0819.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTMDbiote21.68%CRMDCorMedix34.18%NAGENiagen Bioscience15.41%PHVSPharvarisN/AInsider OwnershipCompanyInsider OwnershipBTMDbiote24.00%CRMDCorMedix5.20%NAGENiagen Bioscience9.39%PHVSPharvaris11.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTMDbiote19454.71 million46.78 millionNot OptionableCRMDCorMedix3067.83 million57.52 millionOptionableNAGENiagen Bioscience12078.77 millionN/AN/APHVSPharvaris3052.29 million46.10 millionNot OptionableBTMD, PHVS, CRMD, and NAGE HeadlinesRecent News About These CompaniesPharvaris reports promising results for deucrictibant in HAEJune 3 at 11:28 PM | investing.comPharvaris reports promising results for deucrictibant in HAEJune 3 at 11:28 PM | investing.comPharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume - Time to Buy?June 3 at 12:39 PM | marketbeat.comPharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in ...June 2 at 7:41 AM | gurufocus.comPharvaris (PHVS) Spotlights Promising Deucrictibant Data at Key Workshop | PHVS Stock NewsJune 2 at 7:41 AM | gurufocus.comPharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in ...June 2 at 7:41 AM | gurufocus.comPharvaris Reports Promising Durability Data for Deucrictibant in Treating Hereditary Angioedema and Highlights Potential for Expanded Use in Bradykinin-Mediated AngioedemaJune 2 at 7:19 AM | quiverquant.comPharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated AngioedemaJune 2 at 7:00 AM | globenewswire.comPharvaris N.V.: Pharvaris Reports First Quarter 2025 Financial Results and Provides Business UpdateJune 1, 2025 | finanznachrichten.dePharvaris (NASDAQ:PHVS) Shares Up 6.7% - Time to Buy?May 30, 2025 | marketbeat.comWoodline Partners LP Makes New Investment in Pharvaris (NASDAQ:PHVS)May 28, 2025 | marketbeat.comNorthern Trust Corp Purchases 76,188 Shares of Pharvaris (NASDAQ:PHVS)May 28, 2025 | marketbeat.comVR Adviser LLC Has $61.73 Million Stock Holdings in Pharvaris (NASDAQ:PHVS)May 22, 2025 | marketbeat.comSoleus Capital Management L.P. Grows Holdings in Pharvaris (NASDAQ:PHVS)May 21, 2025 | marketbeat.comBank of America Securities Keeps Their Sell Rating on Pharvaris (PHVS)May 21, 2025 | theglobeandmail.comPharvaris Announces Abstract Acceptance for Presentation at Key Angioedema Congresses in 2025May 19, 2025 | quiverquant.comPharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming CongressesMay 19, 2025 | globenewswire.comPharvaris (NASDAQ:PHVS) Shares Sold by Sphera Funds Management LTD.May 18, 2025 | marketbeat.comPatient Square Capital LP Sells 34,738 Shares of Pharvaris (NASDAQ:PHVS)May 16, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Shares Acquired by Octagon Capital Advisors LPMay 15, 2025 | marketbeat.comPharvaris’s Promising Pipeline Progress and Strong Financial Position Justify Buy Rating with $43 TargetMay 14, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBTMD, PHVS, CRMD, and NAGE Company Descriptionsbiote NASDAQ:BTMD$3.54 -0.01 (-0.28%) As of 06/4/2025 04:00 PM Easternbiote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.CorMedix NASDAQ:CRMD$12.38 -0.23 (-1.82%) As of 06/4/2025 04:00 PM EasternCorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Niagen Bioscience NASDAQ:NAGE$11.72 -0.06 (-0.51%) As of 06/4/2025 04:00 PM EasternNiagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.Pharvaris NASDAQ:PHVS$16.62 -0.66 (-3.82%) As of 06/4/2025 04:00 PM EasternPharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Robinhood Stock Keeps Giving Investors Reasons To Buy CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast Guidewire Rockets Higher: A Move Above $300 Is Probable TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Intuit's AI Boom: Stock Soaring, But Should Investors Hit Pause? Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge Analog Devices' Cyclical Recovery Story Has Just Begun Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
